676 related articles for article (PubMed ID: 18199920)
21. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
22. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
23. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
[TBL] [Abstract][Full Text] [Related]
24. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
[TBL] [Abstract][Full Text] [Related]
25. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
[TBL] [Abstract][Full Text] [Related]
26. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
Littlejohn TW; Majul CR; Olvera R; Seeber M; Kobe M; Guthrie R; Oigman W;
Postgrad Med; 2009 Mar; 121(2):5-14. PubMed ID: 19332958
[TBL] [Abstract][Full Text] [Related]
27. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial.
Vogt L; Navis G; Köster J; Manolis AJ; Reid JL; de Zeeuw D;
J Hypertens; 2005 Nov; 23(11):2055-61. PubMed ID: 16208149
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo.
Manolis AJ; Reid JL; de Zeeuw D; Murphy MB; Seewaldt-Becker E; Köster J;
J Hypertens; 2004 May; 22(5):1033-7. PubMed ID: 15097245
[TBL] [Abstract][Full Text] [Related]
30. Effect of valsartan, hydrochlorothiazide, and their combination on 24-h ambulatory blood pressure response in elderly patients with systolic hypertension: a ValVET substudy.
Duprez DA; Weintraub HS; Cushman WC; Purkayastha D; Zappe D; Samuel R; Izzo JL
Blood Press Monit; 2011 Aug; 16(4):186-96. PubMed ID: 21747241
[TBL] [Abstract][Full Text] [Related]
31. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Deeks ED
Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
[TBL] [Abstract][Full Text] [Related]
33. Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy.
Weinberger MH; Glazer RD; Crikelair NA; Chiang YT
J Hum Hypertens; 2010 Dec; 24(12):823-30. PubMed ID: 20182456
[TBL] [Abstract][Full Text] [Related]
34. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy.
Weir MR; Levy D; Crikelair N; Rocha R; Meng X; Glazer R
Am J Hypertens; 2007 Jul; 20(7):807-15. PubMed ID: 17586417
[TBL] [Abstract][Full Text] [Related]
35. Improving blood pressure control: increase the dose of diuretic or switch to a fixed-dose angiotensin receptor blocker/diuretic? the valsartan hydrochlorothiazide diuretic for initial control and titration to achieve optimal therapeutic effect (Val-DICTATE) trial.
White WB; Calhoun DA; Samuel R; Taylor AA; Zappe DH; Purkayastha D
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):450-8. PubMed ID: 18550935
[TBL] [Abstract][Full Text] [Related]
36. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.
Zheng Z; Lin S; Shi H
J Clin Hypertens (Greenwich); 2010 Jun; 12(6):414-21. PubMed ID: 20591086
[TBL] [Abstract][Full Text] [Related]
37. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
38. Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Calhoun DA; Crikelair NA; Yen J; Glazer RD
Adv Ther; 2009 Nov; 26(11):1012-23. PubMed ID: 20024680
[TBL] [Abstract][Full Text] [Related]
39. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study.
Yarows SA; Oparil S; Patel S; Fang H; Zhang J
Adv Ther; 2008 Dec; 25(12):1288-302. PubMed ID: 19066757
[TBL] [Abstract][Full Text] [Related]
40. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
